Zhong Guo Jing Ying Bao·2025-12-15 16:12Core Viewpoint - Fosun Pharma plans to invest 1.412 billion yuan to acquire a controlling stake in Green Valley Pharmaceutical, aiming to enhance its product pipeline in the central nervous system degenerative disease sector [5] Group 1: Acquisition Details - The acquisition will be executed through purchasing existing shares from original shareholders and subscribing to newly registered capital, resulting in Fosun Pharma holding 51% of Green Valley Pharmaceutical [5] - Green Valley Pharmaceutical's assessed valuation is 1.674 billion yuan [5] Group 2: Product Information - Green Valley Pharmaceutical's main product is the mannitol sodium capsule for treating Alzheimer's disease, which has been suspended from production since November 2024 due to the expiration of its registration certificate [5][6] - The product was conditionally approved for market entry in November 2019 and included in the national medical insurance drug list in 2021 [5] Group 3: Financial Performance - Green Valley Pharmaceutical reported owner equity of 22.98 million yuan in 2023, -16.43 million yuan in 2024, and 10.36 million yuan as of September 30, 2025 [6] - The company achieved revenues of 378 million yuan in 2023, 572 million yuan in 2024, and 102 million yuan in the first nine months of 2025, with a net profit of 31.48 million yuan in 2023, 70.77 million yuan in 2024, and a loss of 67.61 million yuan in 2025 [6] Group 4: Operational Challenges - Green Valley Pharmaceutical faced operational challenges, including the closure of its office and production areas related to the mannitol sodium capsule in June 2025 [7] - The company was fined 400,000 yuan for illegal kickback practices aimed at increasing drug sales, involving 587 academic meetings and significant financial misconduct from July 2022 to July 2024 [7][8]